IO Biotech to Present at 42nd Annual Cowen Healthcare Conference
IO Biotech (Nasdaq: IOBT) announced its participation in the 42nd Annual Cowen Health Care Conference, occurring virtually from March 7-9, 2022. CEO Dr. Mai-Britt Zocca will engage in the Novel IO Panel Discussion on March 7 at 10:30 AM EST. A webcast of the panel will be accessible via the company's website until April 9, 2022. IO Biotech focuses on developing immune-modulating cancer therapies through its T-win® technology platform, with ongoing clinical studies for its lead candidate, IO102-IO103.
- None.
- None.
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today it will present at the 42nd Annual Cowen Health Care Conference to be held virtually March 7 – 9, 2022. At the conference, IO Biotech CEO Dr. Mai-Britt Zocca will participate in the Novel IO Panel Discussion.
Presentation Details
Date and Time: Monday, March 7, 2022 at 10:30 – 11:30 a.m. EST
Webcast Link: https://wsw.com/webcast/cowen108/panel6/2251422
A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com until April 9, 2022.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).
For further information, please visit www.iobiotech.com
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Company Contact:
Mai-Britt Zocca, Ph.D.
CEO and founder of IO Biotech
mz@iobiotech.com
Keith Vendola, M.D.
CFO
IO Biotech, Inc.
kv@iobiotech.com
Investor Inquiries:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
646-606-1438
rmina@lifescicomms.com
FAQ
What will IO Biotech present at the Cowen Health Care Conference?
When is IO Biotech's presentation at the Cowen Conference?
Where can I watch IO Biotech's presentation?
What technology does IO Biotech use for cancer therapies?
What is the focus of IO Biotech's clinical studies?
